ArticlePloS one2014
Population structure among mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Colombia.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Trial
- Transmission ofEpidemiology and infection · 2025Article
- Global epidemiology of Mycobacterium tuberculosis lineage 4 insights from Ecuadorian genomic data.Scientific reports · 2025Article
- Molecular epidemiology ofJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Comparative Genomic Analysis ofTropical medicine and infectious disease · 2024Article
- Comparative genomics of drug-resistant strains of Mycobacterium tuberculosis in Ecuador.BMC genomics · 2022Article
- Synthesis, Anticancer and Antitubercular Properties of New Chalcones and Their Nitrogen-Containing Five-Membered Heterocyclic Hybrids Bearing Sulfonamide Moiety.International journal of molecular sciences · 2022Article
- Dual RNA Sequencing ofInternational journal of molecular sciences · 2022Article
- Pan-genome association study ofFrontiers in microbiology · 2022Article
- Genetic Diversity ofFrontiers in cellular and infection microbiology · 2022Article
- Genetic diversity and drug susceptibility of Mycobacterium tuberculosis in a city with a high prevalence of drug resistant tuberculosis from Southeast of Mexico.BMC infectious diseases · 2021Article
- Whole genome analysis of extensively drug resistant Mycobacterium tuberculosis strains in Peru.Scientific reports · 2021Article
- [National Network for Knowledge Management, Research, and Innovation in Tuberculosis in ColombiaRede Nacional de Gestão do Conhecimento, Pesquisa e Inovação em tuberculose na Colômbia].Revista panamericana de salud publica = Pan American journal of public health · 2021Article
- [Patient- and provider-related factors in the success of multidrug tuberculosis treatment in ColombiaFatores de êxito do tratamento da tuberculose multirresistente relacionados com o paciente e com a equipe de saúde na Colômbia].Revista panamericana de salud publica = Pan American journal of public health · 2021Article
- Patient- and provider-related factors in the success of multidrug-resistant tuberculosis treatment in Colombia.Revista panamericana de salud publica = Pan American journal of public health · 2021Article
- Diversity ofTuberculosis research and treatment · 2021Article
- Article
- Population structure and genetic diversity of Mycobacterium tuberculosis in Ecuador.Scientific reports · 2020Article
- Infection of Monocytes From Tuberculosis Patients With Two Virulent Clinical Isolates ofFrontiers in cellular and infection microbiology · 2020Article
- Human Alveolar and Splenic Macrophage Populations Display a Distinct Transcriptomic Response to Infection WithFrontiers in immunology · 2020Article
Corrections and comments
- Erratum issuedFerro, Beatriz Elena [corrected to Ferro, Beatriz Eugenia]
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhylogeographic composition of M. tuberculosis populations reveals associations between lineages and human populations that might have implications for the development of strategies to control the disease. In Latin America, lineage 4 or the Euro-American, is predominant with considerable variations among and within countries. In Colombia, although few studies from specific localities have revealed differences in M. tuberculosis populations, there are still areas of the country where this information is lacking, as is a comparison of Colombian isolates with those from the rest of the world. PRINCIPAL
findingsA total of 414 M. tuberculosis isolates from adult pulmonary tuberculosis cases from three Colombian states were studied. Isolates were genotyped using IS6110-restriction fragment length polymorphism (RFLP), spoligotyping, and 24-locus Mycobacterial interspersed repetitive units variable number tandem repeats (MIRU-VNTRs). SIT42 (LAM9) and SIT62 (H1) represented 53.3% of isolates, followed by 8.21% SIT50 (H3), 5.07% SIT53 (T1), and 3.14% SIT727 (H1). Composite spoligotyping and 24-locus MIRU- VNTR minimum spanning tree analysis suggest a recent expansion of SIT42 and SIT62 evolved originally from SIT53 (T1). The proportion of Haarlem sublineage (44.3%) was significantly higher than that in neighboring countries. Associations were found between M. tuberculosis MDR and SIT45 (H1), as well as HIV-positive serology with SIT727 (H1) and SIT53 (T1).
conclusionsThis study showed the population structure of M. tuberculosis in several regions from Colombia with a dominance of the LAM and Haarlem sublineages, particularly in two major urban settings (Medellín and Cali). Dominant spoligotypes were LAM9 (SIT 42) and Haarlem (SIT62). The proportion of the Haarlem sublineage was higher in Colombia compared to that in neighboring countries, suggesting particular conditions of co-evolution with the corresponding human population that favor the success of this sublineage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.